EU/3/18/2098: Orphan designation for the treatment of papillary thyroid cancer



Please note that this product (marketed as Vitrakvi) was withdrawn from the Community Register of designated orphan medicinal products in July 2019 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

On 19 November 2018, orphan designation (EU/3/18/2098) was granted by the European Commission to Bayer AG, Germany, for larotrectinib for the treatment of papillary thyroid cancer.

Key facts

Active substance
Intended use
Treatment of papillary thyroid cancer
Orphan designation status
EU designation number
Date of designation

Bayer AG
51368 Leverkusen
Tel. +49 30 300 139 003

Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Vitrakvi at the time of marketing authorisation.

The sponsor formally requested the withdrawal of the orphan designation prior to the Committee’s final opinion. More information is available in the PDF icon orphan designation withdrawal assessment report .

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating